Your browser doesn't support javascript.
loading
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz, S; O'Connor, O A; Pro, B; Trümper, L; Iyer, S; Advani, R; Bartlett, N L; Christensen, J H; Morschhauser, F; Domingo-Domenech, E; Rossi, G; Kim, W S; Feldman, T; Menne, T; Belada, D; Illés, Á; Tobinai, K; Tsukasaki, K; Yeh, S-P; Shustov, A; Hüttmann, A; Savage, K J; Yuen, S; Zinzani, P L; Miao, H; Bunn, V; Fenton, K; Fanale, M; Puhlmann, M; Illidge, T.
Afiliación
  • Horwitz S; Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: horwitzs@mskcc.org.
  • O'Connor OA; University of Virginia Cancer Center, University of Virginia, Charlottesville, USA.
  • Pro B; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
  • Trümper L; Universitätsmedizin Göttingen, Göttingen, Germany.
  • Iyer S; MD Anderson Cancer Center/University of Texas, Houston, USA.
  • Advani R; Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford, USA.
  • Bartlett NL; Washington University School of Medicine, St. Louis, USA.
  • Christensen JH; Odense University Hospital, Odense, Denmark.
  • Morschhauser F; CHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France.
  • Domingo-Domenech E; Institut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Rossi G; Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
  • Kim WS; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Feldman T; John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, USA.
  • Menne T; Freeman Hospital, Newcastle upon Tyne, UK.
  • Belada D; Fourth Department of Internal Medicine - Haematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
  • Illés Á; Debreceni Egyetem, Debrecen, Hajdu-Bihar, Hungary.
  • Tobinai K; National Cancer Center Hospital, Tokyo, Japan.
  • Tsukasaki K; Saitama Medical University International Medical Center, Saitama, Japan.
  • Yeh SP; China Medical University Hospital, Taichung, Taiwan.
  • Shustov A; University of Washington Medical Center, Seattle, USA.
  • Hüttmann A; Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany.
  • Savage KJ; Department of Medical Oncology and University of British Columbia, BC Cancer, Vancouver, Canada.
  • Yuen S; Calvary Mater Newcastle Hospital, Waratah, Australia.
  • Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Miao H; Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Bunn V; Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Fenton K; Seagen Inc., Bothell, USA.
  • Fanale M; Seagen Inc., Bothell, USA.
  • Puhlmann M; Seagen Inc., Bothell, USA.
  • Illidge T; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK.
Ann Oncol ; 33(3): 288-298, 2022 03.
Article en En | MEDLINE | ID: mdl-34921960
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico / Antígeno Ki-1 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico / Antígeno Ki-1 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido